We have previously shown that the adenoviral 12S E1A protein modulates the phosphorylation status of p130 and p107 without apparent changes in the cell cycle dependent phosphorylation of the retinoblastoma protein.
Introduction
The retinoblastoma protein (pRB), p107 and p130 are the three known members of the retinoblastoma family of proteins, also designated as pocket proteins. pRB is the product of the retinoblastoma tumor suppressor gene and is structurally and functionally related to the p107 and p130 proteins. Members of the retinoblastoma family suppress growth at least in part by inhibiting E2F-dependent transcription of genes whose products are required for DNA synthesis and/or for cell cycle progression. This blockage is released by phosphorylation of pocket proteins (for review see GranÄ a et al., 1998; GranÄ a, 1997, 1998) . The phosphorylation status of the pRB family is regulated in a cell cycle entry-progression-and exit-dependent manner in normal cells. In normal resting cells in the G0 phase, pRB, and p107 when detectable, are found hypophosphorylated, whereas p130 is resolved as two bands by SDS ± PAGE corresponding to dierently phosphorylated forms (named p130 forms 1 and 2) (Mayol et al., 1995) . As cells are re-stimulated to enter the cell cycle and progress through mid-G1, the three pocket proteins are abruptly hyperphosphorylated most likely by G1 cyclin/CDK complexes Weinberg, 1995) . While involvement of these complexes in the phosphorylation of the three pocket proteins is widely accepted, there is not yet a precise and complete understanding of the speci®c phosphorylation sites targeted by individual cyclin/CDKs at particular points of the cell cycle. Recent studies in this direction have provided speci®c information in phosphorylation events targeting pRB and their consequences (Harbour et al., 1999; Zhang et al., 2000) . However, it is not known whether equivalent phosphorylation events target p130 and/or p107.
p130 phosphorylation patterns are highly conserved in normal mammalian cells of dierent origin. Hyperphosphorylation of p130 results in a band shift to a more slowly migrating band, which we named p130 form 3. Phosphorylation of p130 to form 3 might be linked to its stability since it is followed by dramatic downregulation of p130 as cells progress through S phase and mitosis (Mayol et al., 1995 (Mayol et al., , 1996 Smith et al., 1998) . As cells exist mitosis to enter the next G1 phase, the three pocket proteins become hypophosphorylated. There is compelling evidence that at least in the case of pRB, this shift to hypophosphorylated forms occurs by the action of speci®c protein phosphatases (Ludlow and Nelson, 1995) .
p130 forms with atypical mobility have been detected in cells expressing the adenoviral E1A 12S oncoprotein. The primary form of p130 in E1A expressing cells exhibits a faster mobility than p130 form 3; we have named this faster migrating form, form 2b (Mayol et al., 1995; ParrenÄ o et al., 2000) . For instance, form 2b is the primary form of p130 in 293 cells growing asynchronously or in MC3T3-E1 cells engineered to express E1A at similar levels. Previous experiments have shown that E1A blocks both hyperphosphorylation of p130 to form 3 and hyperphosphorylation of p107, with little change in the phosphorylation status of pRB (ParrenÄ o et al., 2000) . This is consistent with results showing that the phosphorylation status of pRB, but not p130 or p107, is modulated in a cell cycle dependent manner in 293 cells. The block to hyperphosphorylation of p130 and p107 is not the result of E1A physically masking certain phosphorylation sites as a result of the E1A/pocket protein interaction. Interestingly, while E1A appears to have only one speci®c eect on blocking hyperphosphorylation of p107, E1A exhibits two distinct eects on p130 phosphorylation: (i) block to hyperphosphorylation to form 3 and; (ii) induction of phosphorylation to form 2b. Low levels of E1A expression are sucient for the ®rst eect, but higher expression of E1A is required for the induction of phosphorylation to form 2b (ParrenÄ o et al., 2000) .
When protein extracts from mammalian cells expressing E1A are incubated with extracts containing the three forms of p130, E1A exhibits a clear binding preference for p130 forms 1 and 2 (Mayol et al., 1995) . This suggested that the block to hyperphosphorylated form 3 observed in 293 cells might function to ensure that all p130 forms are compromised by E1A. However, whether p130 form 3 interacts with E1A in vivo is not known since E1A and p130 form 3 do not coexist in vivo. The abrupt changes in the phosphorylation patterns of p130 and p107 observed in E1A expressing 293 cells are in contrast with pRB maintaining cell cycle-dependent modulation of its phosphorylation patterns in these cells. The presence of hyperphosphorylated forms of pRB, which do not associate with E1A, do not seem to be an obstacle for E1A/E1B-mediated transformation of these cells, presumably because phosphorylation inactivates them. Independently of whether E1A can associate with p130 form 3 in vivo, it is conceivable that p130 form 3 possesses a function, which is inactivated by E1A preventing full hyperphosphorylation of p130 to form 3. This function is not the E2F transcriptional repressor activity of p130, since E1A disrupts this p130 function through direct binding, and p130 form 3 does not associate with E2F-4 (Mayol et al., 1996) . Alternatively E1A may be inactivating a function of p130 form 3 perhaps as CDK inhibitor (Castano et al., 1998; Coats et al., 1999; De Luca et al., 1997; Woo et al., 1997; Zhu et al., 1995) . The idea that the presence of hyperphosphorylated p130 is not compatible with the transformation induced by DNA tumor viruses is supported by studies with SV40. SV40 large-T antigen (TAg), which also associates with and inactivates the pRB family of proteins, has been shown to induce downregulation of hyperphosphorylated p130 through protein degradation (Stubdal et al., 1996 (Stubdal et al., , 1997 . Thus, two dierent tumor viruses have evolved to inactivate p130 through two completely dierent mechanisms, suggesting that p130 form 3 performs a cellular function whose inactivation may contribute to cellular transformation. This function of p130 is not shared by pRB, since hyperphosphorylated forms of pRB are not targeted by E1A, and coexist in E1A expressing cells. This supports the suggestion that blocking the appearance of p130 form 3 is a basic part of the mechanism by which E1A redirects growth and dierentiation controls in normal mammalian cells.
While the eects of E1A on p130/p107 phosphorylation have been described (ParrenÄ o et al., 2000) , the mechanisms by which E1A dierentially modulates the phosphorylation status of pocket proteins are not known. In this report we have investigated the mechanisms responsible for the abnormal modulation of phosphorylation of p130 and p107 in cells expressing adenoviral E1A. We have determined whether certain phosphorylation sites are aected by E1A. We have also identi®ed two distinct types of CDK complexes, whose dierential modulation results in changes in the phosphorylation status of both p130 and p107. Moreover, we have also found that although modulation of certain phosphorylation events by E1A is dependent on disrupting pocket-protein/E2F pathways, others are not.
Results
We have previously shown that cells expressing the adenoviral E1A 12S oncoprotein (hereafter E1A protein) exhibit a blockage in hyperphosphorylation of p130 to form 3 and hyperphosphorylation of p107. In addition, in cells expressing relatively high levels of E1A protein such as human 293 cells or MC3T3-E1 cells stably expressing similar levels of E1A, p130 is phosphorylated to a form with an abnormal mobility (ParrenÄ o et al., 2000) . We previously named this form p130 form 2b (Mayol et al., 1995; ParrenÄ o et al., 2000) . In cells expressing lower levels of E1A, or in cells expressing E1A mutants that do not bind pocket proteins, full induction of p130 phosphorylation to form 2b is compromised (ParrenÄ o et al., 2000) . We have also shown that ectopic expression of individual G1/S cyclins in 293 cells does not overcome the block to hyperphosphorylation of p130 to form 3 induced by E1A (ParrenÄ o et al., 2000) . This suggested that either expression of more than one cyclin is required to overcome the E1A eect or that in 293 cells it is not possible to overcome a potential E1A-mediated downregulation of CDK activities by ectopically expressing cyclin regulatory subunits. To test these hypotheses we cotransfected p130 with a combination of G1/S cyclins (cyclins D1, D3, E and A) into 293 cells. Figure 1A (upper panel) shows that this combination of cyclins is also unable to rescue the E1A mediated block in p130 hyperphosphorylation to form 3 in these cells. In contrast, this same combination of cyclins completely rescued the E1A mediated block in hyperphosphorylation of p130 to form 3 in U-2 OS cells transiently expressing E1A ( Figure 1A , lower panel). 293 cells express other adenoviral proteins in addition to E1A, which may aect the pathways leading to activation of G1/S cyclin/CDK complexes. Since our observation on U-2 OS cells transiently expressing E1A was extended to other cell types (see below), we decided to determine the mechanisms used by E1A to modulate pocket proteins in cells in which E1A is the only adenoviral protein expressed.
We and others, have used 6% SDS ± PAGE as a reliable method to assess changes in the phosphorylation status of pocket proteins (see Introduction). Here, we wanted to determine speci®cally whether there was a particular set of phosphorylation sites in p130 whose phosphorylation was altered by E1A. To this end, we transfected p130 encoding vectors alone or with vectors encoding E1A, G1/S cyclins or a combination of these vectors into U-2 OS cells. One set of transfections was analysed by Western blot using anti-p130 antibodies, while another set of transfected cells was metabolically labeled with 32 P-orthophosphate to perform phosphopeptide maps of p130 (see below). Figure 1A (lower panel) and 1B shows that the eect of E1A on p130 hyperphosphorylation in U-2 OS cells is rescued by coexpression of a combination of G1/S cyclins, including cyclins D1, D3, E, and A ( Figure 1D , compare lanes f and g). Coexpression of p130 and G1/S cyclins results in complete hyperphosphorylation of p130 to form 3 (a single band is observed, Figure  1B , lane e). Transfection of p130 alone resulted in a mix of forms (forms 1, 2, 3 and unphosphorylated p130) because at the level of p130 expression and cell density required for this experiment, the endogenous cyclins are partially limiting for full hyperphosphorylation of p130 to form 3 in U-2 OS cells ( Figure 1B , lane d). These results also strongly indicate that p130 form 3 is the most hyperphosphorylated form of p130. The observation that the E1A block on p130 phosphorylation is rescued by overexpression of a combination of G1/S cyclins suggests that E1A directly interferes with hyperphosphorylation of p130 by G1/S cyclin/CDK complexes (see below).
The other set of transfected cells was metabolically labeled with 32 P-orthophosphate and ectopic p130 was immunoprecipitated with anti-HA antibodies. p130 phosphorylated forms were resolved by SDS ± PAGE and analysed by autoradiography. p130 phosphorylation patterns are comparable to those seen by Western blot ( Figure 1B,C) . Obviously the most hyperphosphorylated forms incorporated more radioactivity. Thus, these forms are enriched vs the less phosphorylated forms detected by Western blot analysis (compare Figures 1B and C) . The p130 phosphorylated forms were then eluted from the gel and trypsinized as described previously (Boyle et al., 1991) . Phosphopeptide maps were obtained by TLC electrophoresis in pyridine/acetic buer by using the Hunter System followed by thin layer chromatography in pyridine/ acetic/butanol buer (see experimental procedures). Figure 1D shows that p130 is phosphorylated at multiple sites. As mentioned above, with these levels of expression of ectopic p130 and cell density, the endogenous cyclins were less ecient in fully phosphorylating p130 to form 3 ( Figure 1B and C, compare lanes d). Coexpression of G1/S cyclins and p130 leads to hyperphosphorylation of p130 to form 3 ( Figure 1B and C, lane e) and this coincides with a slight increase in the relative intensity of a few phosphopeptides (Figure 1 , compare panels D and E: phosphopeptides 1, 2, 5 and 6, see also panel G). Thus, ectopic expression of at least certain G1/S cyclins reproduces phosphorylation of p130 by endogenous kinases (see below). This also suggests that these phosphopeptides contain G1/S cyclin/CDK target sites. To further prove this, a p130 mutant with a mutated potential CDK phosphorylation site (Ser 1044 -to-Ala) was also cotransfected with the combination of cyclins ( Figure  1H ). Comparison of Figure 1E and H clearly shows that phosphopeptide 2 is not detected in the p130 mutant. This indicates that p130 Ser 1044 is an in vivo phosphorylatable site, which is contained in peptide 2.
Coexpression of p130 and E1A results in a clearly dierent pattern with a reduced number of phosphopeptides ( Figure 1 , compare F to D, E and G). The phosphopeptides E1, E2, E3 and E4 contain the major phosphorylation sites of p130 when co-expressed with E1A. Interestingly, coexpression of p130, E1A, and the cyclin combination, results in a pattern of phosphopeptides that is very similar to the pattern seen when p130 is cotransfected with the cyclin combination in the absence of E1A (Figure 1 , compare E and G). These results suggest that E1A blocks the phosphorylation of CDK sites on p130 by limiting the activities of at least certain G1/S cyclin/CDK complexes.
The eects of E1A in the phosphorylation status of p130 in 293 cells could not be rescued by overexpression of individual (ParrenÄ o et al., 2000) or combined G1/S cyclins ( Figure 1A , upper panel). In contrast, the same combinations of cyclins eciently rescued the block to hyperphosphorylation of p130 to form 3 induced by E1A in U-2 OS cells ( Figure 1A and B). Thus, we rationalized that overexpression of individual G1/S cyclins or combinations or certain cyclins could be sucient to overcome the block induced by E1A in U-2 OS cells. Figure 2 shows that D-type cyclins but not cyclins E or A, completely rescue the E1A-mediated block to hyperphosphorylation of p130 form 3 (lanes 2 to 7). Interestingly, in the presence of E1A, both cyclins E and A individually or combined seem to induce hyperphosphorylation of p130 form 1 to more phosphorylated species with a mobility between forms 2 and 3 (form 2b) (Figure 2 , compare lane 3 to lanes 6, 7 and 12). Note that these species migrate slightly faster than the form induced by D-type cyclins. p130 form 2b is the primary form of Figure 1 E1A block on p130 hyperphosphorylation to form 3 is rescued by a combination of G1/S cyclins in U-2 OS cells: E1A blocks the phosphorylation of speci®c CDK sites. (A) 293 and U-2 OS cells were transfected with the indicated combination of vectors. 293 cells stably express E1A. Thirty-six hours upon transfection cells were harvested and protein lysates were obtained. p130 phosphorylation patterns were determined by Western blot analysis. At total of 15 mg of whole protein lysate was loaded per well. Proteins were resolved by 6% SDS ± PAGE followed by Western blot analysis using anti-p130 antibodies. Dierently phosphoryated HA-p130 forms are indicated. In these gels form 2 and 2b are not resolved. (B) U-2 OS cells were transfected with the indicated combination of vectors as described in the Materials and methods section and indicated in the ®gure. Twenty-four hours after transfection the cells were harvested. A total of 30 mg of whole protein lysate was loaded per well. Proteins were resolved by 6% SDS ± PAGE followed by Western blot analysis as above. Dierently phosphorylated HA-p130 forms are indicated. (B and C) Lanes are indicated by lower case letters that match their corresponding phosphopeptide maps panels (C ± H) U-2 OS cells were transfected with the indicated combination of vectors as described in the Materials and methods section. Thirty hours upon transfection the cells were washed with phosphate-free medium and incubated in phosphate-free medium for 1 h. 1 mCi of [ 32 P]orthophosphate was added per plate and the cells were incubated for 2.5 h at 378C in a 5% CO 2 incubator. Cells were then collected and lysed. Ectopically expressed p130 was immunoprecipitated with anti-HA antibodies. The immunoprecipitates were resolved by 6% SDS ± PAGE and the dry gel was exposed to ®lm (C). (C) Lane d was exposed for a longer period of time than the other lanes in this gel since there was less incorporation of radioactivity into p130 when cotransfected alone under these experimental conditions (see text). (D ± H) Gel slices containing phosphorylated HA-p130 were obtained and p130 was eluted from the gel and incubated with trypsin. The resulting tryptic digest was resolved by TLC electrophoresis followed by chromatography as described in the Materials and methods section. The primary p130 tryptic phosphopeptides in cells expressing E1A are designated (Mayol et al., 1995; ParrenÄ o et al., 2000) . Our previous work (ParrenÄ o et al., 2000) , suggested that E1A had two separate eects on p130: (i) block in hyperphosphorylation of p130 to form 3; and (ii) induction of phosphorylation of p130 to form 2b when E1A was expressed at relatively high levels. This second eect was lacking in cells expressing lower levels of E1A. The results shown in Figure 2 suggested that the block in hyperphosphorylation to form 3 could result from E1A mediated downregulation of Dtype cyclin/CDK activities, since this block is rescued by D-type cyclins but not completely by cyclins E and/ or A. In addition, these results also suggest that the induction of hyperphosphorylation to intermediate species of p130 (form 2b) seen in cells expressing high levels of E1A could result from E1A-mediated upregulation of endogenous cyclins E and/or A. However, since ectopic expression of D-type cyclins might indirectly result in upregulation of endogenous cyclins E and A, we could not rule out that cyclin E could be required to hyperphosphorylate p130 to form 3 and that this activity could also be compromised by E1A. Thus, to analyse the individual eects of cyclin D1 and cyclin E on the E1A mediated block, without indirect eects due to endogenous cyclins, we cotransfected cyclin D1 in the presence of dominant-negative CDK2 (CDK2-dn) (to block endogenous cyclin E and A/CDK2 complexes) and cyclin E in the presence of Together this demonstrates that although cyclin E/ CDK2 and cyclin A/CDK2 and possibly other kinases (Canhoto et al., 2000; Mayol et al., 1996) are involved in hyperphosphorylation of p130 in normal cells, the block in hyperphosphorylation to p130 form 3 mediated by E1A is likely to result from downregulation of D-type cyclin/CDK activities (see below). The cooperation of both D-type cyclin/CDK complexes and cyclin E/CDK2 complexes in the phosphorylation of p130 is suggested because p16 and CDK2dn are more ecient than p16 alone in blocking cyclin D1 induction of p130 hyperphosphorylation ( Figure 3 , compare lanes 4 and 6). Under these experimental conditions, cotransfection of p130 and E1A results in a pattern of forms that includes primarily forms 2/2b and form 1 (form 2b cannot always be resolved from form 2 by gradient SDS ± PAGE). Coexpression of p130 and E1A with cyclin E vectors induces the prevalence of forms 2/2b versus form 1 ( Figure 3 compare lanes 2 and 7; this is also seen in Figure 2 ). This pattern is not signi®cantly aected by coexpression of p16 ( Figure 3 , compare lanes 7 and 8).
However, phosphorylation of p130 to form 2/2b in E1, E2, E3 and E4. The remaining tryptic phosphopeptides are numbered. Coexpression of a combination of G1/S cyclins in the presence or absence of E1A induces the phosphorylation of phosphopeptides (1, 2, 4, 5 and 6). (H) HA-p130pmS1044A encodes a p130 protein, in which a potential phosphorylation site for CDKs has been mutated by site directed mutagenesis (see the Materials and methods section). HA-p130pmS1044A was cotransfected with a combination of G1/S cyclins. Comparison of the phosphopeptide pattern with panels E or G clearly reveals the absence of phosphopeptide 2. An empty circle indicates the expected migration for the absent phosphopeptide the presence of E1A is clearly inhibited when the activity of cyclin E is blocked by CDK2-dn ( Figure 3 , lane 9). When both CDK2-dn and p16 are cotransfected with cyclin E, inhibition to phosphorylation of p130 to form 2/2b is slightly more impaired. This might be the result of a p16 indirect eect in the activity of cyclin E and/or cyclin A, most likely as a result of releasing p27/p21 from CDK4/6 complexes. The released p27/p21 CKIs have been shown to bind CDK2 complexes and inhibit their activity (McConnell et al., 1999; Mitra et al., 1999) . Altogether these results suggest that E1A modulates the phosphorylation status of p130 by blocking D-type cyclin activity and by inducing cyclin E and/or A activities. Cyclin D/CDK activity can be deregulated by dierent mechanisms. These mechanisms include downregulation of the regulatory subunit and/or the upregulation of CKIs among others. Previously, it has been shown that E1A downregulates the expression of D-type cyclins in a number of cell types (Alevizopoulos et al., 1998; Cenciarelli et al., 1999; Spitkovsky et al., 1994) . It has also been shown that cells lacking a functional pRB express high levels of p16 (Parry et al., 1995; Serrano et al., 1993; Tam et al., 1994; Yeager et al., 1995) . However, involvement of p16 in E1A-mediated eects on phosphorylation of p130 and p107 is unlikely since E1A blocks hyperphosphorylation of both pocket proteins in U-2 OS cells (ParrenÄ o et al., 2000) , which do not expres p16 (McConnell et al., 1999; Mitra et al., 1999) . Thus, we asked the question of whether the E1A-mediated changes in p130 and p107 phosphorylation could be explained by changes in the expression of G1/S cyclins.
To address this question we utilized clones of MC3T3-E1 osteoblasts stably expressing dierent levels of E1A (clones G1 and G2) and an E1A mutant (E1Amt2) that does not associate with the pRB family of proteins (Beck et al., 1998; ParrenÄ o et al., 2000) . The eects of E1A expression on p130 phosphorylation status are shown in the upper panel of Figure 4A for reference. Figure 4A shows that stable overexpression of E1A and E1Amt2 results in dramatic downregulation of the three D-type cyclins (D1, D2 and D3). At least for cyclins D1 and D2, this eect appears to be dose dependent (compare levels of Dtype cyclins and E1A). Thus, these data together with the results shown in Figures 2 and 3 strongly suggest that the blockage of full hyperphosphorylation of both p130 and p107 is the consequence of E1A-mediated downregulation of D-type cyclins. In addition, the fact that the E1A mutant behaves as wild type E1A demonstrates that the E1A domains required for binding to pocket proteins are not required to downregulate D-type cyclins or to block hyperphosphorylation of p130 and p107.
On the other hand, stable overexpression of E1A in MC3T3-E1 osteoblasts results in upregulation of cyclins E and A ( Figure 4A, compare lanes 1 and 2) . Cyclin A appears to be upregulated more eciently than cyclin E. As expected, this eect is dose dependent, being the upregulation of cyclins E and A lower in clone G2 than in clone G1. These results strongly suggest that a certain threshold of expression of these cyclins is required to induce hyperphosphorylation of p130 to form 2b (p130 form 2b is the primary form detected in cells expressing high levels of E1A). In addition, Figure 4A shows that E1A-mediated upregulation of cyclins E and A is dependent on the E1A residues essential for binding to pocket proteins, since the E1Amt2 is at least partially impaired in its ability to upregulate cyclins E and A (compare lanes 3 and 4, considering the levels of E1A expression in these clones). Upregulation of cyclins E and A is accompanied by increased CDK2 kinase activity, as measured in CDK2 complexes immunopuri®ed with anti-cyclin E, anti-cyclin A and anti-CDK2 antibodies ( Figure 4B , compare lanes 2 and 3). Altogether, these results suggest that changes in the expression of various G1/S cyclins are responsible for E1A mediated eects of p130 phosphorylation. These results were unexpected, because pRB is also phosphorylated by the same G1/S cyclin/CDK complexes, and we have previously shown that expression of E1A in 293 cells does not disrupt the cell cycle dependent phosphorylation of pRB (ParrenÄ o et al., 2000) . In addition, ectopic expression of E1A in U-2 OS cells failed to noticeably modulate the phosphorylation patterns of pRB (ParrenÄ o et al., 2000) . It is conceivable that in the absence of D-type cyclins, pRB might be phosphorylated by other CDK complexes at similar sites (i.e. cyclin E and/or A/CDK2) in cells expressing E1A (see Discussion).
The experiments described in Figures 1 ± 3 using U-2 OS cells were performed by transient transfection and relied on the expression of high levels of exogenous proteins in a small percentage of the cell population. Thus, we wanted to determine the eects of overexpressing D-type cyclins and cyclin E on endogenous p130 and p107 in normal murine cells, which were previously engineered to stably express E1A (Beck et al., 1998) . The purpose of these experiments was also to determine whether endogenous p130 and p107 are aected dierentially by the two E1A dependent pathways that modulate p130 phosphorylation. To transduce MC3T3-E1 cells stably expressing E1A, we used replication-defective recombinant adenoviruses (Albrecht and Hansen, 1999) . Under our experimental conditions most cells are transduced as determined with a control adenovirus that expresses the EGFP ( Figure 5A ). Anti-p130 polyclonal antibodies (C-20) cross-react with a protein (indicated by an asterisk, Figure 5C ) that migrates more slowly than all p130 forms. This helps monitor the dierences in migration of p130 forms. (p130 form 3 migrates closer to this cross-reacting protein than the other p130 forms.) Transduction with cyclin D1 adenoviruses results in hyperphosphorylation of endogenous p130 to form 3. (Notice that p130 in these lanes migrates as close to the cross-reacting band as the p130 form 3 detected in exponentially growing MC3T3 cells; Figure 5C , lanes 1, 2 and 4). Cyclin D2 adenoviruses did not completely rescue the E1A mediated block most likely because the Figure 4 E1A modulates dierentially the expression of G1/S cyclins in MC3T3-E1 pre-osteoblasts. (A) Protein expression levels of D-type cyclins, cyclins E and A in exponentially growing parental MC3T3-E1 cells and MC3T3-E1 cells stably expressing wild type E1A (G1, G2) or the E1A mutant YH47/928 (mt 2 ) were determined by Western blot analysis (lower panels). The expression of E1A and the phosphorylation status of p130 were also monitored by Western blot analysis (upper panels). Whole protein extracts from the indicated stable clones were resolved by 12% SDS ± PAGE or 6% SDS ± PAGE (for p130) and analysed by Western blot with the corresponding antibodies. The cyclin D2 antibody cross-reacts with cyclin D1. Relevant proteins are indicated. (B) The kinase activities associated with cyclin E, cyclin A or CDK2 were determined from the same protein samples shown in Figure 4A . Kinase complexes were immunoprecipitated with the indicated antibodies. An irrelevant anity puri®ed antibody (anti-HA) and normal rabbit serum (NRS) were used as negative controls. The kinase activity of the immunocomplexes was determined by using the exogenous substrate histone H1 (hH1) level of expression of cyclin D2 in the transduced cells was lower than the level of cyclin D1 ( Figure 5B and C, lane 5, indicated by a bracket). Cyclin E adenoviruses had no eect ( Figure 5C , lane 6, compare with lane 7 for clarity). This was expected because this cell line expresses sucient levels of E1A to induce complete hyperphosphorylation of p130 to form 2b in the absence of any exogenous cyclin. Transduction with cyclin D1 and cyclin D2 adenoviruses results in hyperphosphorylation of p107 ( Figure 5C , lower panel). Consistent with the lower expression of cyclin D2, the block to hyperphosphorylation of p107 is not completely rescued. However, cyclin E does not appear to aect p107 phosphorylation. These results are in agreement with previous work suggesting that D-type cyclins, but not cyclin E, phosphorylate p107 (Beijersbergen et al., 1995) . These results are also consistent with the fact that in cells stably expressing E1A mutants defective in binding to pocket proteins, p107 hyperphosphorylation is blocked as eciently as cells expressing similar levels of wild type E1A (ParrenÄ o et  al., 2000) .
Since E1A blocks hyperphosphorylation of p130 to form 3, cells stably expressing this form of p130 and E1A do not exist. Because transduction with recombinant cyclin D1 adenoviruses results in full hyperphosphorylation of endogenous p130, we asked the question of whether p130 form 3 interacts with E1A in vivo. Figure 6 shows that p130 form 3 interacts with E1A as eciently as with p130 form 2b in MC3T3-E1 cells stably expressing E1A. These results were completely unexpected since a previous experiment had shown that p130 forms 1 and 2 exhibit high preference over p130 form 3 for binding to E1A in vitro (Mayol et al., 1995) . Thus, this result suggest that the E1A mediated block in hyperphosphorylation of p130 to form 3 is not in place to ensure a block in abrogation of the p130/E1A interaction, since all phosphorylated forms of p130 are now known to associated with E1A in vivo (Figure 6 ).
It has been previously shown that cells lacking functional pRB express high levels of p16, which leads to downregulation of D-type cyclin/CDK activity and therefore should aect the phosphorylation status of p130. Since modulation of the Rb pathway might be Figure 5 Ectopic expression of cyclins D1 or D2, but not cyclin E, rescues endogenous p130 and p107 from the hyperphosphorylation block induced by stable expression of E1A in murine MC3T3-E1 pre-osteoblasts. E1A expressing MC3T3-E1 cells (clone G1) were infected with either adenovirus control (Ad-EGFP) (A) or the following recombinant adenoviruses, Adcyclin D1, Ad-cyclin D2 or Ad-cyclin E individually or in combination at a MOI of 30 p.f.u./cell (B). (A) Transduction eciency was estimated by assessing the number of EGFP positive cells under a¯uorescent inverted microscope. Transduction eciency was near 100%. (B) Levels of cyclin E (upper panel), cyclin D1 (middle panel) and cyclin D2 (lower panel) were determined by Western blot analysis using speci®c antibodies (note cross-reaction of cyclin D1 and D2 antibodies). (C) The phosphorylation status of p130 was determined by 6% SDS ± PAGE followed by Western blot analysis using anti-p130 antibodies. p130 from E1A expressing MC3T3-E1 cells (clone G1) migrates as form 2b (ParrenÄ o et al., 2000) . A total of 30 mg of whole protein lysate was loaded per well. The mobility of p130 and p107 forms is indicated by dots. Open dot (*) indicates p130 forms 2/2b and hypophosphorylated p107 and closed dot (*) indicates hyperphosphorylated p130 or p107. (*) An asterisk indicates the mobility of a cross-reacting band that helps compare the migration of p130 forms. i.e.; p130 form 3 in lanes 1, 4 and 7 migrates closer to the cross-reacting band than form 2b (lanes 2, 6 and 9). Brackets denote partial eects induced by the cyclin D2 recombinant adenoviruses due most likely to lower expression E1A differentially modulates p130 targeting CDKs M Parren Äo et al important at least for one of the eects of E1A on p130 phosphorylation, we compared the eects on p130 phosphorylation in cells lacking functional pRB versus cells expressing E1A. As expected, cells lacking functional pRB, including HeLa, Saos-2, Y79, WERI and C33A cells, also lack hyperphosphorylated p130 form 3 (Figure 7 ). However, in contrast to cells expressing E1A, there is not constitutive hyperphosphorylation of p130 to form 2b ( Figure 7A , compare lanes 4 to 5 and 6; Figure 7B , compare lanes 2 ± 7 to lane 1). This is likely to occur because in pRB minus cells most of the E2F-regulated genes including the cyclin A gene are still normally regulated (Hurford et al., 1997) . In addition, p130 and p107 might at least partially, perform some of the functions of pRB in these cells. In E1A expressing cells, however, the three pocket proteins are inactive in their ability to repress the transcription factor E2F. This results in upregulation of CDK2 activity in these cells, which in turn leads to hyperphosphorylation of p130 to form 2b.
Discussion
We have previously shown that E1A modulates the phosphorylation status of p130 and p107 (ParrenÄ o et al., 2000) . In this report we have determined the mechanisms responsible for this modulation. We show that E1A dierentially modulates the phosphorylation of p130 phosphorylatable sites. This results in a relative decrease in the phosphorylation of certain sites versus other sites. Reduced phosphorylation of a subset of sites correlates with blocking of hyperphosphorylation this is independent of the E1A domains required to inactivate pocket proteins. The same mechanism seems to be responsible for the E1A-mediated block on p107 hyperphosphorylation. However, E1A also in¯uences p130 phosphorylation through a separate pathway that results in phosphorylation of p130 to form 2b. Our results strongly suggest that this occurs as a consequence of E1A-mediated induction of CDK2 activity, which results from increased expression of cyclins E and/or A. This second component of E1A-mediated modulation of p130 phosphorylation is dependent at least in part on the pocket protein-binding domain of E1A. Surprisingly, modulation of various G1/S CDK complexes by E1A has dierential consequences in the phosphorylation of the three pocket proteins. Our results also unveil that cell cycle dependent phosphorylation of p130 results from the concerted action of D-type cyclin/CDKs, cyclin E/CDK2 and perhaps cyclin A/ CDK2 complexes (Figure 8) . Mayol et al., 1995 Mayol et al., , 1996 . These G1/S cyclin/CDK-independent phosphorylation events are indicated by a double P (PP) below the p130 molecule. The phosphorylation sites on p130 in T98G quiescent cells have been identi®ed recently (Canhoto et al., 2000) . In mid-G1 p130 is hyperphosphorylated by D-type cyclin/CDK complexes (indicated by a light grey-boxed P on top of the p130 molecule). At the G1/S onset transition and during S phase, p130 is further phosphorylated by Cyclin E/CDK2 complexes and probably also by cyclin A/CDK2 complexes (indicated by a dark grey-boxed P). Whether D-type cyclin/CDK complexes are sucient to generate p130 form 3 is not known (question mark), but even if this is the case, it is clear from our results that cyclin E, and perhaps also cyclin A, further phosphorylate p130. Additional phosphorylation by these complexes may not change further the mobility of p130, but may regulate other properties of p130 such as its protein stability. (Lower panel) In cells expressing high levels of E1A, p130 forms characteristic of quiescent cells are not detected. However, it is not known whether the sites on p130 phosphorylated in quiescent cells are phosphorylated in E1A expressing cells (indicated by a double P and a question mark). E1A downregulates the expression of D-type cyclins by dierent means. At least one of the mechanisms for cyclin D1 downregulation may involve E1A-mediated inactivation of p300 (Albanese et al., 1999) . The consequence of blocking expression of D-type cyclins is inhibition of D-type cyclin/CDK activity and a block in hyperphosphorylation of p107 and hyperphosphorylation of p130 to form 3 (indicated by a crossed-out light grey-boxed P and crossed-out pathway). In contrast, E1A upregulates the expression of cyclins E and A and this results in upregulation of the kinase activity of cyclin E/CDK2 and cyclin A/CDK2 (indicated by a thicker arrow between p130 molecules). This is likely to occur, at least in part, by the ability of E1A to block pocket protein inhibition of E2F-dependent transcription E1A differentially modulates p130 targeting CDKs M Parren Äo et al
E1A affects the activity of two distinct groups of CDKs
Two distinct E1A activities appear to be involved in the modulation of pocket protein phosphorylation. The ®rst activity blocks full hyperphosphorylation of both p130 and p107. The second activity induces phosphorylation of p130 to form 2b. In regard to the ®rst activity, our results show that E1A-mediated downregulation of D-type cyclins is eciently rescued by ectopic expression of these regulatory subunits; this restores full phosphorylation of p130 and p107. Complete block to full hyperphosphorylation of p130 to form 3 is seen even when E1A is expressed at low levels (Figure 4 and ParrenÄ o et al., 2000). Of note, p130 seems to be more sensitive to the eects of E1A than p107 since at lower levels of E1A p107 hyperphosphorylation is blocked only partially (ParrenÄ o et al., 2000) . These results suggest that a small decrease in D-type cyclin/CDK activity below a certain threshold is sucient to fully block hyperphosphorylation of p130 to form 3. E1A residues essential for binding of pocket proteins (Moran, 1993) are not required to downregulate D-type cyclins and block full hyperphosphorylation of both p130 and p107. It has been previously shown that E1A induces downregulation of D-type cyclins in a number of cell types (Alevizopoulos et al., 1998; Cenciarelli et al., 1999; Spitkovsky et al., 1994 Spitkovsky et al., , 1995 . A recent study has shown that E1A 12S inhibits the cyclin D1 promoter (Albanese et al., 1999) . This inhibition requires the E1A amino terminal p300/CBP-binding domain. Interestingly, p300, but not CBP, induces the cyclin D1 promoter (Albanese et al., 1999) . Thus, it is conceivable that the E1A-mediated block in full hyperphosphorylation of p130/p107 depends, at least in part, on the ability of E1A to sequester p300. However, this might not be the only mechanism (Figure 8 ). Our preliminary data show that E1A mutants lacking essential p300/ CBP binding residues still block hyperphosphorylation of p130. This suggests that inactivation of p300 is not sucient for this E1A eect and that other E1A domains are responsible for this E1A activity. Experiments are in course to fully elucidate the domains of E1A involved in blocking hyperphosphorylation of p130 and p107.
The E1A-mediated block on p130 phosphorylation to form 3 seems to be the result of downregulation of D-type cyclins. This block can be rescued by ectopically expressing D-type cyclins in U-2 OS and MC-3T3-E1 cells (this report) and T98G cells (data not shown). However, D-type cyclins, individually or in combination with other G1/S cyclins cannot rescue this eect of E1A in 293 cells. It is possible that ectopic expression of D-type cyclins in 293 cells is not sucient to upregulate D-type cyclin/CDK activity to the levels required to hyperphosphorylate p130 to form 3. This could be a cell-type speci®c eect and/or the result of the expression of other adenoviral oncoproteins in these cells (E1B 19K and 55K) . The speci®c reasons for the dierent behavior of 293 cells remain to be elucidated.
The second E1A activity seems to aect p130, but not p107. This activity is dose dependent. Thus, phosphorylation of p130 to form 2b occurs when E1A is expressed at a certain threshold, but not when E1A expression is low. Ectopic expression of both cyclins E or A mimic the eects induced by E1A, and E1A induces the activation of CDK2 in a dose dependent manner. An E1A mutant lacking residues essential for binding to pocket proteins and inactivation of their E2F transcriptional repressor activity is largely impaired in both its ability to upregulate CDK2 activity and phosphorylation of p130 to form 2b. Thus, this second E1A activity that modulates p130 phosphorylation status requires E1A binding to one or more pocket proteins. To determine whether inactivation of pRB was sucient for this eect, we examined whether in pRB-minus cells, p130 was constitutively phosphorylated to form 2b as it occurs in cells expressing high levels of E1A. Our results show that inactivation of pRB is not sucient to induce constitutive phosphorylation of p130 to form 2b. A likely scenario is that inactivation of pRB is not sucient to upregulate all the E2F activities that ultimately result in induction of CDK2 activity. In this regard it is known that in pRB minus cells, cyclin E is upregulated (Herrera et al., 1996; Hurford et al., 1997) . However, the presence of p130 and/or p107 in pRB minus cells might be sucient to normally regulate the expression of at least certain E2F target genes including the cyclin A gene. Thus, it is very likely that higher expression of cyclins E and/or A than what is observed in pRB-minus cells is required to induce constitutive phosphorylation of p130 to form 2b. This is the scenario found in cells expressing E1A over a certain threshold. Lack of p130 form 3 in pRBminus cells was reported when this manuscript was in preparation (Cheng et al., 2000) . It was shown that in pRB-minus cells p130 form 2b is generated coinciding with cell cycle-dependent upregulation of CDK2 activity (late G1 and S phases of the cell cycle). These results are in keeping with our observations and further highlight that generation of p130 form 2b is dependent on CDK2 activity.
It is important to highlight that cellular signals that aect G1/S CDKs in a distinct manner exhibit distinguishable eects on p130 phosphorylation. TGF-b treatment of HaCat cells results in G1 arrest as result of the cooperative action of CKIs, which inhibit both D-type cyclin/CDKs and CDK2 complexes (Reynisdottir et al., 1995) . This results in a block in hyperphosphorylation of p130 and accumulation of p130 primarily as form 1 (Mayol et al., 1996) . The phosphorylation pattern of p130 in the presence of TGF-b exhibits a striking similarity with the eects that ectopic coexpression of p16 and CDK2dn has on p130 phosphorylation (Figure 3 and data not shown). This strongly suggests that both types of CDKs cooperate to hyperphosphorylate p130. In this regard it is important to point out that E1A, which blocks Dtype cyclin/CDK activity, but not CDK2 activity (E1A induces CDK2), does not generate the same forms of p130 as TGF-b.
The net eect of E1A on p130 phosphorylation is a relative change in the level of phosphorylation of p130 phosphorylatable sites. The phosphorylation of peptides labeled E1, E2, E3 and E4 prevails over the phosphorylation of peptides labeled 1, 2 and 6 ( Figure  1 ). Ectopic expression of a combination of G1/S cyclins restores hyperphosphorylation of p130 to form 3 and phosphorylation of peptides 1 to 6, suggesting that these sites are CDK sites. We have identi®ed one of these sites as Ser
1044
. This site is a CDK consensus site (Ser-Pro) conserved in the three pocket proteins. The corresponding site in pRB, Ser
795
, is eciently phosphorylated by CDK4, but not CDK2 or CDK3 in vitro. Mutation of this site in pRB prevents pRB inactivation by CDK4 in a microinjection assay (Connell-Crowley et al., 1997) . Downregulation of p130 Ser 1044 phosphorylation by E1A strongly suggests that this site is targeted by D-type cyclin/CDKs. When this manuscript was in preparation, the identi®cation of several p130 in vivo phosphorylation sites was reported (Hansen et al., 2001) . This report provided evidence that D-type cyclin/CDKs are responsible for the phosphorylation of a subset of the identi®ed sites. The data reported here is agreement with their conclusions.
One intriguing question that remains is how is it possible that the dierential modulation of various cyclin/CDK complexes known to be involved in the phosphorylation of pRB has little eect on pRB cell cycle dependent phosphorylation. We have previously shown that E1A blocks cell cycle dependent phosphorylation of both p130 and p107, but not pRB in 293 cells, and that the patterns of pRB phosphorylated forms change little in U-2 OS cells ectopically expressing E1A (ParrenÄ o et al., 2000) . One possibility is that in the absence of D-type cyclin/CDK activity in E1A expressing cells, other cyclin/CDK complexes are capable of phosphorylating sites on pRB normally phosphorylated by D-type cyclin/CDK complexes. In contrast, this does not occur to p130 or p107. Another signi®cant dierence regarding E1A eects on pocket protein phosphorylation is that p107 is not aected by the second E1A activity mentioned above. It is likely that this occurs because p107 is not a primary substrate of cyclin E and/or A/CDK2 complexes in vivo (Beijersbergen et al., 1995) . Altogether, this further highlights that phosphorylation of pocket proteins is a complex and dierential process. Moreover, it is interesting to stress that the speci®city of E1A activities towards phosphorylation of the three pocket proteins as well as the dierential eect on various cyclin/CDK complexes provides an excellent model system to further study the numerous pathways that modulate phosphorylation of pocket proteins.
DNA tumor viruses and modulation of p130 phosphorylation
This report, together with previous studies, shows that at least two DNA tumor viruses, adenovirus (ParrenÄ o et al., 2000) and SV40 (Stubdal et al., 1996 (Stubdal et al., , 1997 induce changes in the phosphorylation status of both p130 and p107. Interestingly, these two tumor viruses utilize completely dierent mechanisms to modulate and presumably inactivate p130. The dierences are: (1) SV40 TAg requires an LXCXE domain to induce changes in the phosphorylation patterns of p130 and p107, while E1A blocks full hyperphosphorylation of these two proteins independently of the pocket protein binding domain through inhibition of D-type cyclin/ CDKs; (2) TAg, unlike E1A, induces degradation of p130 through the proteasome pathway; (3) the changes induced by TAg on both p130 and p107 require a Jdomain present in TAg, which is not present in E1A.
The domains in T antigen required to modulate the phosphorylation status of p130 and p107 and stability of the p130 protein are required for cellular transformation. At least one domain of E1A involved in the modulation of p130 phosphorylation is also necessary for cellular transformation. However, the contribution of p130 phosphorylation changes to the cellular programs induced by E1A is not known yet. We have shown here that p130 form 3 associates in vivo with E1A. This was an unexpected result given our previous data showing that p130 forms 1 and 2 exhibit a clear preference over form 3 for binding to E1A in an in vitro assay (Mayol et al., 1995) . Thus, preventing phosphorylation of p130 to form 3 is not designed to ensure binding of all cellular p130 to E1A. However, it is conceivable that p130 form 3 has a function, whose inactivation is important for the adenoviral life cycle. TAg might accomplish the same objective by inducing degradation of p130. Finally, one might also argue that the eects induced by TAg and E1A on p130 could be just consequences of the numerous pathways that are aected by the expression of these viral proteins. However, this latter possibility contrasts with the fact that the J-domain of TAg confers a growth advantage to wild type Mouse Embryo Fibroblasts (MEFs), but not to MEFs lacking both p130 and p107 (Stubdal et al., 1996 (Stubdal et al., , 1997 . This suggests that inactivation of p130 and/or p107 by the J-domain of TAg contributes to the transforming activities of TAg. Further experiments are warranted to fully determine the contribution of each E1A domain to the changes in hyperphosphorylation of p130 and/or p107. It will also be important to elucidate the speci®c advantage of modulating the phosphorylation status of pocket proteins to the cellular reprogramming induced by E1A.
Materials and methods

Cell culture
U-2 OS, 293, HeLa, T98G and HaCat cell lines were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) (Cellgro) supplemented with 10% fetal bovine serum (FBS) (Sigma). pRB mutant cell lines, Y79, WERI, Saos-2 and C33A, were grown in the same conditions. MC3T3-E1 parental cells were grown in Alpha MEM, Earle's with glutamine and nucleoside medium (a-MEM) (Cellgro) plus 10% FBS. Generation of MC3T3-E1 cells expressing wild type E1A 12S (clone G1 and G2) and E1A 12S mutant YH47/928 (mt2) proteins has been described (Beck et al.,
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Transient transfections
U-2 OS were plated at a density of 60 ± 80% in 100 mm plates and grown overnight. Cells were re-fed 4 h before transfection. Transfections were carried out following standard calcium-phosphate DNA precipitation procedure (Ausubel et al., 1996; Garriga et al., 1996a) . Cells were harvested 48 h upon transfection. See ®gure legends for speci®c amounts of DNA used in each experiment.
Plasmids
The Rc/cyclin D1, Rc/cyclin D3, Rc/cyclin E and Rc/cyclin A vectors were provided by P Hinds (Hinds et al., 1992) . The pCMV-p16 and the pCMV-CDK2-dn vectors were provided by E Harlow (Koh et al., 1995; Serrano et al., 1993; van den Heuvel and Harlow, 1993) . The ptTAs vector is a pCMV vector kindly provided by C Lee and EP Reddy (Raghunath et al., 2000) . The ptTAs-HA-p130, pcDNAI-E1A wild type (12S) and pcDNAI-E1A mutant 928/961(mt1) (12S) plasmids were described previously (ParrenÄ o et al., 2000) . ptTAs-HAp130pm S1044A was generated by site directed mutagenesis using the polymerase chain reaction (PCR)-based QuikChange mutagenesis kit (Stratagene). The mutant was veri®ed by DNA sequence analysis.
Antibodies
Anti-p130-CT (sc-317), anti-p107 (sc-318), anti-cyclin D3 (sc-182), anti-cyclin E (sc-481), anti-p16 (sc-468), anti-CDK2 (sc-163), anti-HA-probe (sc-805) rabbit polyclonal antibodies; anti-cyclin D1 (sc-8396), anti-cyclin E (sc-247) mouse monoclonal antibodies and anti-cyclin D2 (sc-452) rat monoclonal antibody were obtained from Santa Cruz Biotechnology. Anti-p130 mAb (R27020) was from Transduction Laboratories. Anti-HA monoclonal antibodies (12CA5 mAb) were purchased from Roche. Rabbit polyclonal anti-Cyclin A antibody was a gift from J Pines. M73 anti-E1A monoclonal antibody was a gift from E Harlow.
Adenovirus production and infection
Recombinant adenoviruses (Ad-Cyclin D1, Ad-Cyclin D2 and Ad-Cyclin E) were generated previously (Albrecht and Hansen, 1999) . Adenoviruses encoding EGFP (Ad-EGFP) were a gift of P Ruiz. Viral stocks were ampli®ed using 293 cells and were puri®ed by using CsCl density gradient centrifugation. Viral titers were determined by plaque assay (Becker et al., 1994) . MC3T3-E1 cells expressing wild type E1A 12S (clone G1, Beck et al., 1998) were plated at 0.6610 6 cells per 100 mm plate in a-MEM containing 10% FBS. Twenty-four hours later, the cells were re-fed with 3 ml of fresh medium and infected at a MOI of 30 p.f.u./cell for 5 h. Then, cells were replenished with fresh medium and harvested after 48 h. Transduction eciency was assessed by monitoring the expression of EGFP in cells transduced with Ad-EGFP under the inverted-¯uorescent microscope.
Western blot analysis
Whole protein lysates were obtained essentially as described previously Mayol et al., 1995) . Brie¯y, cells were lysed in lysis buer containing 50 mM Tris-Cl (pH 7.4), 5 mM EDTA, 250 mM NaCl, 50 mM NaF, 0.1% Triton X-100, 0.1 mM Na 3 VO 4 , 2 mM PMSF, 10 mg/ml leupeptin, 4 mg/ml aprotinin and 4 mg/ml pepstatin (lysis buer). Western blots were performed as previously described Mayol et al., 1995) . Brie¯y, protein extracts (25 ± 50 mg) were resolved by SDS ± PAGE and transferred to PVDF membranes (Immobilon-P, Millipore) in 10 mM CAPS (pH 11) containing 10% methanol. Twelve per cent gels were run to determine the expression of cyclins, CDK2, p16 and E1A proteins and 6 or 4 ± 6% gradient gels to determine the phosphorylation status of pocket proteins. The transferred membranes were probed with speci®c primary antibodies and the corresponding horseradish peroxidase-conjugated secondary antibody (Amersham). Bands were visualized by incubating the membranes with Enhanced Chemiluminescence reagent (NEN) and exposing the membranes to X-ray ®lm.
In vitro kinase assays CDK2 kinase activity was determined from CDK2, cyclin E and cyclin A immunopuri®ed complexes. Complexes were immunoprecipitated with speci®c antibodies from whole protein extracts (100 mg) from parental MC3T3-E1 cells, MC3T3-E1 cells stably expressing wild type E1A 12S (clone G1 and G2) and E1A 12S mutant (YH47/928). In vitro kinase assays were performed using histone H1 as exogenous substrate as described previously (ParrenÄ o et al., 2000) .
Phosphopeptide mapping
U-2 OS cells were transfected with combinations of plasmids as indicated in the corresponding ®gure. Fifteen mg of ptTAs-HA-p130 or ptTAs-HA-p130 pm S1044A, 5 mg of pcDNA/ E1A and/or 3 mg of each of cyclins (Rc/cyclin D3, Rc/cyclin D1, Rc/cyclin E and Rc/cyclin A). Forty-eight hours after transfection the plates were washed with phosphate free DMEM, and incubated for 1 h in phosphate free DMEM containing 10% dialyzed FBS. Then, 1 mCi of [ 32 P]orthophosphate (NEN) was added to each plate and the cells were kept at 378C in a 5% CO 2 incubator for 2.5 h. Whole protein lysates were obtained and the ectopically expressed HA-p130 protein was immunoprecipitated with anti-HA antibodies (12CA5 monoclonal antibody, Roche). The immunoprecipitates were resolved by 6% SDS ± PAGE and the phosphorylated forms of HA-p130 were visualized by autoradiography. HA-p130 tryptic phosphopeptides were obtained essentially as described in the Hunter Thin Layer Peptide Mapping Electrophoresis System Manual (Boyle et al., 1991) . The tryptic digest was resolved by electrophoresis on a TLC plate (EM Science) by using a buer containing 1% pyridine/10% acetic acid in water for 30 min at 1200 V. The electrophoresis was run on a HTLE-7000 apparatus (CBS Scienti®c). After electrophoresis, the TLC plate was dried at room temperature and the second dimension was run in a chromatography tank as described earlier (Garriga et al., 1996b) . After chromatography, the TLC plates were dried at 658C and stained with 2% ninhydrin to visualize a peptide mix standard run on the same TLC plate. Tryptic phosphopeptides were visualized by autoradiography at 7708C by using Transcreen-HE intensifying screens and BioMax MS ®lm (Kodak).
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